Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the…
At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as…